<DOC>
	<DOC>NCT00664066</DOC>
	<brief_summary>This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect &amp; describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.</brief_summary>
	<brief_title>DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patients must have established Chronic Kidney Disease (CKD) and be willing and able to provide written informed consent. Patients must already be receiving DYNEPO treatment at time of study entry. Patients who are likely to receive DYNEPO for at least 1 year. Known intolerance to EPO of any of its excipients Known of suspected Pure Red Cell Aplasia (PRCA)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>